Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rotavirus vaccines: targeting the developing world.

Roger I Glass1, Joseph S Bresee, Reina Turcios

  • 1Viral Gastroenteritis Section, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. rglass@cdc.gov

The Journal of Infectious Diseases
|August 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.

NPJ vaccines·2026
Same author

COVID-19 vaccine acceptance and recommendation among health workers in nine countries: a pooled analysis of survey data from 2023 to 2024.

BMJ global health·2026
Same author

Funding the priorities of the influenza vaccines research and development roadmap: an evaluation of global investment.

Vaccine·2025
Same author

Accomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap.

Vaccine·2025
Same author

Lessons learned from the COVID-19 pandemic: opportunities and challenges to leverage investments in HIV, tuberculosis and malaria for pandemic preparedness and response.

BMJ global health·2025
Same author

Severity Scale of Influenza and Acute Respiratory Illness Hospitalizations to Support Viral Genomic Surveillance: A Global Influenza Hospital Surveillance Network Pilot Study.

Influenza and other respiratory viruses·2025
Same journal

NET-inducing ability of Cutibacterium acnes clinical isolates is associated with pathogenicity in acne vulgaris.

The Journal of infectious diseases·2026
Same journal

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

The Journal of infectious diseases·2026
Same journal

Monitoring HLA-A2-restricted T cell responses and BCLA-specific serostatus during human latent Toxoplasma gondii infection suggests the implication of CD8+ T cells in parasite containment.

The Journal of infectious diseases·2026
Same journal

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
Same journal

Type 3 fimbrial regulation underpins anti-MrkA immunotherapeutic efficacy in experimental Klebsiella pneumoniae infection.

The Journal of infectious diseases·2026
Same journal

Rationalising heterogeneity in Staphylococcus aureus bacteraemia: current progress and future goals.

The Journal of infectious diseases·2026
See all related articles

Rotavirus vaccines are crucial for preventing severe diarrhea in children, a leading cause of death globally. Despite challenges, ongoing research and development aim to make these life-saving vaccines accessible worldwide.

Area of Science:

  • Public Health and Vaccinology
  • Pediatric Infectious Diseases
  • Global Health Equity

Background:

  • Rotavirus infection is a primary cause of severe childhood diarrhea, responsible for approximately 440,000 deaths annually.
  • The development of rotavirus vaccines has been a long-standing public health priority due to the disease's significant global burden.
  • The first rotavirus vaccine, RotaShield, was withdrawn due to a rare association with intussusception, highlighting safety considerations.

Purpose of the Study:

  • To review the progress and challenges in developing and implementing rotavirus vaccines, particularly in developing countries.
  • To assess the potential impact of rotavirus vaccination programs on reducing childhood mortality and hospitalizations.
  • To identify key hurdles for vaccine introduction, including efficacy and safety in diverse populations, financing, and public awareness.

Related Experiment Videos

Main Methods:

  • Review of existing literature and clinical trial data for rotavirus vaccines.
  • Analysis of the public health impact and economic burden of rotavirus disease.
  • Examination of regulatory approvals, vaccine licensure, and ongoing research.

Main Results:

  • Two new live oral rotavirus vaccines have completed large-scale trials, with one licensed in Mexico and the Dominican Republic, and the other potentially in the US soon.
  • Demonstrated efficacy in industrialized and middle-income nations, but further proof is needed in low-income African and Asian countries.
  • The risk of intussusception remains a critical safety concern requiring continued monitoring and demonstration of acceptable safety profiles.

Conclusions:

  • Rotavirus vaccines offer substantial benefits for reducing childhood deaths, outweighing rare risks like intussusception in developing nations.
  • Significant challenges persist, including proving vaccine efficacy and safety in resource-limited settings, securing novel financing, and increasing disease/vaccine awareness.
  • Special focus on India, China, and Indonesia is essential due to their high rotavirus mortality rates and reliance on domestic vaccine production.